FDA issues warning over Celebrex, Bextra ads

Share this article:
The FDA has issued a warning letter to Pfizer stating that television and print ads for its painkillers Celebrex and Bextra are misleading to consumers.
A total of five advertisements failed to disclose side effects and other risk information and made "unsubstantiated effectiveness claims," the letter posted on the FDA's Web site Wednesday said.
A company spokeswoman told Reuters the Celebrex ads cited in the letter were no longer running. The spokeswoman had no comment on the other materials including a Bextra patient brochure and a television infomercial.
Pfizer said in a Reuters report it would discuss its next steps with the FDA. The letter gives Pfizer until Jan. 26 to respond.
On Dec. 17, the National Institutes of Health halted a cancer trial using Celebrex after researchers discovered an increased risk of heart attack.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions